Prodrug-tethered lipid nanoparticles for synergistic mRNA cancer immunotherapy
Thursday, July 17, 2025
5:35 PM – 5:46 PM EDT
Introduction: mRNA-based immunotherapy has emerged as a breakthrough strategy for cancer treatment. However, phenotypic regulation of T cells between activated and exhausted stages remains a significant challenge. A potential approach to improve anti-cancer T cell activity could be to simultaneously deliver interleukin (IL-12), to stimulate effector T cells, and indoleamine 2,3-dioygenase (IDO) inhibitor, to suppress T cell exhaustion. Here, we designed prodrug ionizable lipid nanoparticles (pLNPs), conjugating of an IDO inhibitor and encapsulating IL-12 mRNA to achieve synergistic cancer immunotherapy.
Learning Objectives:
At the completion of this activity, participants will know
Understand the screening process used to identify the top LNP for efficient mRNA delivery.
Evaluate the antitumor efficiency of pLNP when combining the IL-12 mRNA with small drug.
Explain the strengths of combination therapy strategy for targeted treatment of solid tumor.
